Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited net product sales of EXPAREL at $113.7 million and iovera° at $2.7 million for Q3 2020. Sales for September were $39.5 million for EXPAREL and $1.1 million for iovera°. EXPAREL average daily sales exceeded prior year levels at 110% for September. The company is optimistic about future growth due to increased demand for EXPAREL in both elective and non-elective procedures. A new Innovation and Training Center in Tampa is set to enhance training for pain management techniques.
Pacira BioSciences (Nasdaq: PCRX) announced a positive opinion from the European Medicines Agency’s CHMP recommending marketing authorization for its pain management drug, EXPAREL, for postsurgical analgesia. This recommendation was supported by four pivotal studies highlighting EXPAREL's effectiveness in reducing pain scores and opioid use in various surgical settings. A final European Commission decision is expected in November 2020. This step aligns with Pacira's vision to lead in non-opioid pain management, with EXPAREL already utilized in over seven million patients in the U.S.
Pacira BioSciences (PCRX) and IPG have announced a partnership aimed at reducing postsurgical opioid prescriptions and lowering surgical costs across IPG's health plan network. The collaboration will see IPG reimbursing for EXPAREL®, a non-opioid pain management solution, to enhance surgical care quality and affordability. Both companies will create educational resources to optimize pain management practices, with Pacira emphasizing the benefits of non-opioid approaches for improved patient outcomes and satisfaction.
PARSIPPANY, N.J., Sept. 11, 2020 - Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 3:30 PM ET. Interested parties can listen to the live audio through the company’s website. A replay will be available for two weeks post-event. Pacira specializes in non-opioid pain management solutions, with its flagship product, EXPAREL®, launched in April 2012. The firm advocates for reduced opioid reliance in healthcare.
Pacira BioSciences (PCRX) reported preliminary August 2020 net product sales of EXPAREL at $36.1 million, reflecting average daily sales at 111% of 2019 levels. The rise in sales is attributed to the growing adoption of EXPAREL among surgical centers and anesthesiologists, driven by a shift towards outpatient procedures as restrictions on elective surgeries ease amid COVID-19. The company aims to provide transparency by reporting monthly sales until full visibility on pandemic impacts is achieved. Financial data is preliminary and unaudited.
Pacira BioSciences (Nasdaq: PCRX) reported Q2 2020 revenues of $75.5 million, down 26% from $102.6 million in Q2 2019, largely due to the impacts of COVID-19. EXPAREL net sales were $73.0 million, also down by 26%. The company’s GAAP net loss reached $7.3 million ($0.17 per share), contrasting with a net income of $2.7 million in the same period last year. Total operating expenses decreased to $82.7 million. Pacira has seen a recovery in EXPAREL sales since April and aims to expand its non-opioid pain management solutions. The FDA accepted an sNDA for EXPAREL for pediatric use, with an expected decision by March 2021.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 9:10 AM ET. Interested parties can access the live audio via the company’s website. A webcast replay will be available for two weeks post-event. Pacira specializes in non-opioid pain management solutions, including EXPAREL® and the iovera⁰ system.
Pacira BioSciences announced the publication of its Phase 4 study results for EXPAREL in Anesthesia and Analgesia. The study showed a 52% reduction in total opioid consumption at 72 hours post-C-section when combined with bupivacaine, and a statistically significant increase in opioid-spared patients (54% vs 25%). The study spanned 13 sites and involved 136 patients. Safety was comparable between groups, with 64% of the EXPAREL group experiencing treatment-emergent adverse events. This data could enhance postoperative pain management strategies, especially given that C-sections pose significant opioid use concerns.
Pacira BioSciences announced that the FDA has accepted its supplemental new drug application (sNDA) for EXPAREL, aiming to expand its label to include postsurgical analgesia for children aged six and over. Based on positive Phase 3 study results showing favorable pharmacokinetics and safety profiles, the FDA's action date is set for March 22, 2021. If approved, EXPAREL will become the first long-acting local anesthetic sanctioned for pediatric use, addressing the urgent need for non-opioid pain management alternatives in children, who typically rely on opioids for post-surgery pain relief.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will report its second quarter financial results on August 6, 2020, before market opening. Following the announcement, a live conference call will take place at 8:30 a.m. ET. Participants can join via a dedicated dial-in number or through a webcast available on the company’s investor page. A replay of the call will be accessible for one week post-event. Pacira specializes in non-opioid pain management and regenerative health solutions, prominently featuring its long-acting analgesic, EXPAREL®, launched in April 2012.